Latest news with #Biote-certified
Business Wire
9 hours ago
- Business
- Business Wire
Biote Names Rich Barrera to Board of Directors
IRVING, Texas--(BUSINESS WIRE)-- biote Corp.(NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that its Board of Directors has elected Rich Barrera to the Board, effective immediately. 'We are pleased to welcome Rich Barrera to Biote's Board of Directors,' said Marc Beer, Executive Chairman of Biote. 'Rich has a distinguished background as an investment professional, founding Roystone Capital in 2012 and managing investment portfolios for more than 20 years. For the past few years, we've had the pleasure of working with Rich and his team at Roystone, which is one of Biote's top institutional shareholders. Rich is fully aligned with our strategy to build long-term value for shareholders and his expertise and insights will be especially valuable as we continue to execute our growth plan.' Mr. Barrera is currently Founder and CEO of Roystone Capital, a New York City-based investment manager. Prior to founding Roystone in 2012, Mr. Barrera co-managed investment portfolios at Redwood Capital Management, LLC from 2009 to 2012 and at Glenview Capital Management from 2002 to 2009. Mr. Barrera served as Chair of the Finance Committee and member of the Audit Committee of Pacific Gas & Electric from 2019 to 2020. Mr. Barrera earned his MBA from Harvard Business School in 1997 and graduated from the Wharton School with a BS in Accounting and Finance in 1993. About Biote Biote is transforming healthy aging through innovative, personalized hormone optimization and therapeutic wellness solutions delivered by Biote-certified medical providers. Biote trains practitioners to identify and treat early indicators of aging conditions, an underserved global market, providing affordable symptom relief for patients and driving clinic success for practitioners. Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words 'may,' 'can,' 'should,' 'will,' 'estimate,' 'plan,' 'project,' 'forecast,' 'intend,' 'expect,' 'anticipate,' 'hope,' 'believe,' 'seek,' 'target,' 'continue,' 'could,' 'might,' 'ongoing,' 'potential,' 'predict,' 'would' and other similar expressions, are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual results or developments to differ materially from those expressed or implied by such forward-looking statements, including but not limited to: anticipated benefits and successful execution of our organizational restructuring; the success of our dietary supplements to attain significant market acceptance among clinics, practitioners and their patients; our customers' reliance on certain third parties to support the manufacturing of bio-identical hormones for prescribers; our and our customers' sensitivity to regulatory, economic, environmental and competitive conditions in certain geographic regions; our ability to increase the use by practitioners and clinics of the Biote Method at the rate that we anticipate or at all; our ability to grow our business; the significant competition we face in our industry; the impact of strategic acquisitions and the implementation of our growth strategies; our limited operating history; our ability to protect our intellectual property; the heavy regulatory oversight in our industry; changes in applicable laws or regulations; changes to international tariffs, U.S. trade policy or similar government actions; geopolitical tensions; the inability to profitably expand in existing markets and into new markets; the possibility that we may be adversely impacted by other economic, business and/or competitive factors, including the impact of hurricane and other natural disasters; and future exchange and interest rates. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and other risks and uncertainties described in the 'Risk Factors' section of the Biote's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission (the 'SEC') on March 14, 2025, and Quarterly Report on Form 10-Q for the three months ended March 31, 2025, filed with the SEC on May 9, 2025, and other documents filed by Biote from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Biote assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Biote does not give any assurance that it will achieve its expectations.
Yahoo
02-04-2025
- Business
- Yahoo
biote Corp. (BTMD): Insider Were Buying In Q1 2025
We recently published a list of . In this article, we are going to take a look at where biote Corp. (NASDAQ:BTMD) stands against other micro-cap stocks insiders were buying in Q1 2025. The White House announced Tuesday that Trump's tariffs would take effect immediately after being unveiled on Wednesday. In anticipation of these 'reciprocal tariffs,' which will apply to all countries, the stock market reacted. By Tuesday morning, the broader market index and Nasdaq Composite dropped by about 0.2%, while blue-chip companies lost 0.06%. Amid ongoing market uncertainty, insider trading often comes under the spotlight. Executive stock purchases can signal optimism, but sales may reflect personal financial decisions or a need to diversify investments. To maintain transparency, executives typically follow pre-arranged strategies, like 10b5-1 plans. While insider trading can offer valuable information, it's important to evaluate it in the broader context of the company's financial stability and current market trends. Today, we're focusing on stocks with micro market capitalizations that have seen significant insider buying in the first quarter of the year. Using Insider Monkey's insider trading screener, we identified companies with market caps under $250 million where at least three insiders purchased shares in the past three months. From this list, we ranked the top 10 stocks with the highest number of insiders making purchases. Stocks that have been recently covered were excluded from our analysis. Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). With each stock, we note the number of insiders who acquired shares in the first quarter and market capitalizations. A Biote-certified practitioner examining a patient's blood sample under a microscope. Number of insiders buying: 5 Market Capitalization: $192.84 million Biote specializes in hormone optimization, offering training and certification for physicians and nurse practitioners in bioidentical hormone replacement therapy. It ranks fifth among the 10 micro-cap stocks insiders were buying in Q1 2025. The Irving, Texas-based company provides a comprehensive practice-building platform, including education, practice management software, inventory tools, and marketing support. Biote also sells dietary supplements and sterile pellet insertion kits for hormone therapy. In March, five insiders, including the company's CEO, acquired a total of $2.79 million worth of biote shares at an average price of $3.75 per share. Currently, the stock trades at $3.63 per share, having dropped 41.26% year-to-date and 37.09% over the past 12 months. For the full year 2024, biote disclosed revenue of $197.2 million, up 6.4% year-over-year. The increase was primarily driven by growth in procedure revenue. Net income attributable to biote stockholders amounted to $3.16 million, compared to $3.32 million in 2023. Gross profit margin for 2024 was 70.5% compared to 68.8% for 2023. The increase in gross profit margin was primarily due to the vertical integration of its 503B manufacturing facility and effective cost management. Adjusted EBITDA for 2024 was $58.2 million, with an adjusted EBITDA margin of 29.5%, compared to adjusted EBITDA of $55.3 million, with an adjusted EBITDA margin of 29.8% for 2023. The consensus rating on biote stock from six analysts is a 'Strong Buy' with a price target of $7.36 per share, reports TipRanks. The average price target suggests a 102.75% upside from the latest price. Overall, BTMD ranks 5th on our list of micro-cap stocks insiders were buying in Q1 2025. While we acknowledge the potential of BTMD our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BTMD but that trades at less than 5 times its earnings, check out our report about the . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
